BCRX BioCryst Pharmaceuticals Inc Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
19:24
May 24
May 24
Buy BCRX ahead of Ph3 topline data in HAE, expecting navenibart to become best-in-class long-acting injectable with existing commercial infrastructure.
MED
14:21
May 21
May 21
Buy BCRX as BoA call takeaways show balance sheet cleanup, no near-term BD risk, and upcoming Navenibart BLA filing, positioning it as an attractive M&A target for specialty pharma.
HIGH
18:19
May 19
May 19
Author adds to ABVX and NKTR positions ahead of key data, expressing bullish conviction on ABVX's high probability of meeting endpoints while holding other biotech names for later review.
HIGH
17:44
May 07
May 07
Long BCRX as part of a concentrated biotech portfolio; limited specific catalyst disclosed.
HIGH
11:47
May 06
May 06
Buy BCRX on the post-earnings dip, citing consensus beat and profitability; the selling is fast-money noise and valuation remains inexpensive.
HIGH
10:59
Apr 24
Apr 24
Buy BCRX ahead of earnings expected to beat on script data, plus other catalysts targeting a year-end price of $21.
MED
14:09
Apr 16
Apr 16
Buy BioCryst Pharmaceuticals as underlying prescription data remains solid and supports the fundamental picture despite ongoing market rumors.
MED
About BCRX Analyst Coverage
Buzzberg tracks BCRX (BioCryst Pharmaceuticals Inc) across 1 sources. 6 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (86%). 7 total trade ideas tracked.